CClinicalTrials.gg
Status unknownNCT02832713GOTOXUpdated Sep 14, 2021

Trial Comparing Botulin Toxin Versus Hyaluronic Acid by Intra-articular Injection for the Treatment of Painful Knee Osteoarthritis

A Phase 2 interventional study of Botulinum toxin A ( BoNT-A) and Hyaluronic acid (HA) in Painful Unilateral Femorotibial Knee Osteoarthritis of Any Etiology, sponsored by University Hospital, Strasbourg, France. Status unknown at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-14.

Sponsored by University Hospital, Strasbourg, France · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Sep 2021), so the status shown — last known as Active, not recruiting — may be out of date.
Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

In France, osteoarthritis affects about 10 million people and knee osteoarthritis represents 35% of cases. It is thought that more than 2.5 million people older than 65 years have knee osteoarthritis.

Currently, osteoarthritis management is based on three major axes:

  1. Non-pharmacological means, such as patient education, loss of weight and physical activity
  2. General pharmacological treatments: mainly paracetamol and then schedule II and III painkillers as well as nonsteroidal anti-inflammatory agent.
  3. Intra-articular pharmacological treatments:

    1. Intra-articular injections of corticosteroids: they are recommended during hydarthrotic flare-ups
    2. Intra-articular injections of hyaluronic acid (HA) (viscosupplementation) in the absence of intra-articular effusion. However, their efficacy is questioned by most experts in the case of symptomatic knee osteoarthrosis.
  4. Sometimes, surgery is the only therapeutic option. However, besides the fact of exposing patients, who are sometimes frail, to several peri- and post-operative complications, the recovery rate (variable according to the prosthesis type and ranging from 5% to 25% at 9 years) in an ageing population justifies waiting as much as possible before surgery. Therefore, it is important to test new therapeutic options for symptomatic osteoarthrosis that will allow postponing the surgical treatment.
  5. The use of botulinum toxin (BoNT-A) could thus represents an interesting alternative. BoNT-A is habitually used by intra-muscular injection for its myorelaxant effect in the management of painful reactive periarticular muscle contractures. However, BoNT-A has also antalgic activity independently of the myorelaxant effect. This allows explaining in part the antalgic effect of intra-articular BoNT-A injection. In the literature, six randomized controlled studies (RCS) have compared BoNT-A and intra-articular injections of corticosteroids, hyaluronic acid, or placebo. Only two RCS concerned knee osteoarthritis and compared BoNT-A to corticosteroids and a placebo, respectively, with a significant antalgic effect only in the groups treated with BoNT-A. No study has compared yet the intra-articular injection of BoNT-A to the viscosupplementation by HA in knee osteoarthritis and this is the aim of this trial.
02

Conditions studied

  • Painful Unilateral Femorotibial Knee Osteoarthritis of Any Etiology

Keywords

  • Knee osteoarthritis
  • Intra-articular botulinum toxin
  • Hyaluronic acid
  • Pain
  • Function
03

In context

Osteoarthritis

4,398 studies on the registry are indexed under Osteoarthritis; 582 are open to participants now.

This study's enrollment of 50 is below the median of 70 across 3,440 interventional studies indexed under Osteoarthritis.

Browse Osteoarthritis studies →

Lead sponsor

University Hospital, Strasbourg, France is the lead sponsor of 966 studies on the registry; 342 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Painful, or predominantly unilateral painful, knee osteoarthritis of any etiology
  • Knee without clinical signs of intra-articular effusion
  • Kellgren score ≥ II on X-ray
  • WOMAC pain sub-score ≥ 5 in the month preceding the inclusion visit

Exclusion criteria

Exclusion Criteria:

Clinical:

  • Inflammatory arthropathy,infectious, neoplastic within the past year
  • Neuromuscular pathology
  • Cardiorespiratory pathology or any other severe disease that interferes with the functional capacities
  • Any decompensated or unstable chronic pathology
  • Glomerular filtration rate (GFR)\<15 mL/min/1.73m²) within the past 6 months
  • HBA1c in diabetic people > 12% within the past 6 months
  • BMI ≥ 35kg/m2
  • Infection: joint, general, distant, cutaneous
  • Foreign material in the knee to be treated: prosthesis, osteosynthesis material
  • Severe coagulation problem: platelets \<100000/mm3 within the past 6 months
  • Allergy to BoNT-A
  • Allergy to HA
  • Pregnant or breast-feeding women
  • Treatment with aminoglycosides or direct oral anticoagulants
  • Treatment with VKA (antihemorrhagic vitamin) if INR (International Normalized Ratio) higher than 3 within the past month
  • Change of anti-pain treatment less than 2 weeks before enrolment
  • Treatment with III pain killers or corticosteroids because of intense pain that does not respond to schedule I and II pain-killers
  • Intra-articular injection of corticosteroids in the previous two months
  • Viscosupplementation and/or injection of BoNT-A in the knee to be treated within the past 6 months
  • Injection of BoNT-A (except the knee to be treated) within the past 3 months
  • Swallowing troubles
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Intra-articular injection of botulinum toxin A

    Drug: Botulinum toxin A ( BoNT-A)

  • Active comparator
    Intra-articular injection of hyaluronic acid

    Device: Hyaluronic acid (HA)

Interventions

  • DrugBotulinum toxin A ( BoNT-A)

    Intra-articular injection of BoNT-A

  • DeviceHyaluronic acid (HA)

    Intra-articular injection of Hyaluronic acid

06

What researchers measure

Primary outcomes

  1. Evaluation of pain measured using the WOMAC pain sub-score

    Time frame: Change from baseline WOMAC pain sub-score at 3 months

Secondary outcomes

  1. Evaluation of the antalgic effect of BoNT-A vs hyaluronic acid measured using a verbal rating scale (VRS)

    Time frame: 1 week after injection

  2. Evaluation of the patients' functional improvement based on the WOMAC score ("stiffness and function sub-score" and total score)

    Time frame: Before injection, 1 month, 3 months and 6 months following injection

  3. Evaluation of the patients' functional improvement using the Timed Up-and-go Test

    Time frame: Before injection, 1 month, 3 months and 6 months following injection

  4. Evaluation of the quality of life based on the SF-36 score

    Time frame: Before injection, 1 month, 3 months and 6 months following injection

  5. Frequency, seriousness and severity of adverse event reactions

    Time frame: during the 6 months following injection

  6. Changes in pain treatment score (using a correspondence table)

    Time frame: Change from baseline pain treatment score at 6 months

  7. Changes in muscular strenght et muscular trophicity (using dynanometer and measure of knee and thin circumference)

    Time frame: Before injection, 1 month, 3 months and 6 months following injection

  8. Changes in passive and active articular knee amplitude, by goniometry

    Time frame: Before injection, 1 month, 3 months and 6 months following injection

07

Study locations

1 site
  • Hôpitaux Universitaires de Strasbourg
    Strasbourg, 67091, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02832713
Lead sponsor
University Hospital, Strasbourg, France
Responsible party
Sponsor
First posted
Jul 14, 2016
Start date
Jun 9, 2017
Primary completion
Oct 2021 (estimated)
Completion
Dec 2021 (estimated)
Last update
Sep 14, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion